Botox Receives FDA Approval for Treatment of Canthal Lines (Crows Feet)
Botox has become a household name when anyone refers to a cosmetic procedure. It’s the Kleenex of the field of injectables on the market. It has been approved by the FDA since 2002 for the temporary improvement of glabellar lines (wrinkles between the eyebrows also referred to as frown lines). Since that 1st FDA approval for the cosmetic use of Botox, doctors have been injecting patients for crow’s feet – wrinkles around the eyes. Patient’s love the results and it really didn’t seem to matter to them that the area treated by Botox was not yet approved. As of Sept. 11, 2013, Botox has been approved by the U.S. Food an Drug Administration for the temporary improvement to the appearance of severe canthal lines, known as crows feet, in adults.
It’s been said “Once you have it – you’ll never live without it”! Americans can’t seem to get enough of Botox with it reported to be a nearly a 1.3 billion dollar industry. Botox was injected almost 6 million times last year on almost 3 million people. It works by blocking the the signal from the nerves to the muscle. The injected muscle can no longer contact. Wrinkles just disappear within about 4 to 5 days after the treatment. The treatment lasts about 4 months in most people.
Now Botox has competition from two similar products, Dysport and Xeomin. All contain bacterium Clostridium botulinum and many studies have been conducted to determine if one works better than the other. Significant differences have not been substantiated. Even so, Botox has a significant lead over the other 2 in sales. It’s such a familiar term, people think it’s the generic term.
The American Society of Plastic Surgeons (ASPS) reported that cosmetic minimally-invasive procedures increased 6% last year. The top 5 minimally invasive procedures were:
- 1. Botulinum toxin type A – Botox, Dysport, Xeomin
- 2. Soft tissue fillers – Radiesse, Restylane, Perlane, Juvederm
- 3. Chemical peel
- 4. Laser hair removal
- 5. Microdermabrasion